France Medical Morphine Market

ID: MRFR/MED/54272-HCR
200 Pages
Rahul Gotadki
Last Updated: February 06, 2026
France Medical Morphine Market Research Report By Route of Administration (Oral, Injectables), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), By Application (Myocardial Infarction, Diarrhea, Arthritis, Kidney Stones, Cancer, Others) and By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Home Care) - Growth & Industry Forecast 2025 To 2035
France Medical Morphine Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.2%
2024 Market Size$ 1,485.84 Million
2025 Market Size$ 1,592.82 Million
2035 Market Size$ 3,193.02 Million
Key Players
Purdue Pharma
Mallinckrodt Pharmaceuticals
Teva Pharmaceutical Industries
Mundipharma
Hikma Pharmaceuticals
Amgen
Trends
  • Regulatory Framework Adjustments
  • Innovative Delivery Systems
  • Focus on Education and Awareness
Opportunities
  • Increased Regulatory Support
  • Rising Pain Management Needs
  • Growing Awareness of Palliative Care
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Food, Beverages & Nutrition, BY Route of Administration (USD Million)
      1. 4.1.1 Oral
      2. 4.1.2 Injectables
    2. 4.2 Food, Beverages & Nutrition, BY Distribution Channel (USD Million)
      1. 4.2.1 Hospital Pharmacy
      2. 4.2.2 Online Pharmacy
      3. 4.2.3 Retail Pharmacy
      4. 4.2.4 Others
    3. 4.3 Food, Beverages & Nutrition, BY Application (USD Million)
      1. 4.3.1 Myocardial Infarction
      2. 4.3.2 Diarrhea
      3. 4.3.3 Arthritis
      4. 4.3.4 Kidney Stones
      5. 4.3.5 Cancer
      6. 4.3.6 Others
    4. 4.4 Food, Beverages & Nutrition, BY End User (USD Million)
      1. 4.4.1 Hospitals and Clinics
      2. 4.4.2 Ambulatory Surgical Centers
      3. 4.4.3 Home Care
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Purdue Pharma (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Mallinckrodt Pharmaceuticals (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Teva Pharmaceutical Industries (IL)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Mundipharma (GB)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Hikma Pharmaceuticals (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Amgen (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sandoz (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Boehringer Ingelheim (DE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    3. 6.3 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    4. 6.4 FRANCE MARKET ANALYSIS BY APPLICATION
    5. 6.5 FRANCE MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
    9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
    12. 6.12 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    13. 6.13 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    14. 6.14 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    15. 6.15 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    16. 6.16 FOOD, BEVERAGES & NUTRITION, BY APPLICATION, 2024 (% SHARE)
    17. 6.17 FOOD, BEVERAGES & NUTRITION, BY APPLICATION, 2024 TO 2035 (USD Million)
    18. 6.18 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 (% SHARE)
    19. 6.19 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
      2. 7.2.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

France Medical Morphine Market Segmentation

France Medical Morphine Market By Route of Administration (USD Million, 2025-2035)

  • Oral
  • Injectables

France Medical Morphine Market By Distribution Channel (USD Million, 2025-2035)

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others

France Medical Morphine Market By Application (USD Million, 2025-2035)

  • Myocardial Infarction
  • Diarrhea
  • Arthritis
  • Kidney Stones
  • Cancer
  • Others

France Medical Morphine Market By End User (USD Million, 2025-2035)

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Home Care

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.